Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Japan To Ban 5,000 Workers From Smoking On The Job (Japan)

This article was originally published in PharmAsia News

Executive Summary

As of April, ahead of Pfizer Japan's planned launch of Chantix (varenicline tartrate), its 5,000 employees are to be barred from smoking while on the job. The company already bans smoking at its Shinjuku headquarters, but it plans to ban the activity at sales sites and other locations, and in the company cars used by the 2,400 sales representatives. Pfizer Japan's smoking policy states it is inappropriate for employees of a health care company to smoke. (Click here for more - may require a subscription

You may also be interested in...



Pfizer’s Champix Approved In Japan

TOKYO - Pfizer is hoping to launch its smoking cessation aid Champix (varenicline) in Japan in April after receiving manufacturing and marketing approval from the Ministry of Health Labor and Welfare Jan. 25, Pfizer Japan told PharmAsia News

Teligent Calls In The Cavalry As Warning Letter Threatens To Overwhelm

Teligent has achieved a “pivotal step in our journey toward securing a strong financial future,” according to management, after recapitalizing its significant debt burden and gaining access to more cash.

Pfizer Partners With Premier To Supply Critical Injectables

Pfizer has entered into an agreement with Premier to supply five essential medications to US healthcare providers through Premier’s ProvideGx program. Both companies aim to secure supply of products specifically used by COVID patients.

UsernamePublicRestriction

Register

LL1129552

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel